HIMS climbs nearly 4% after upbeat earnings and expanded product offerings

Traders Union
All News
Stocks
Hims & hers surges 3.9% today

Highlights

Hims & Hers Health reported Q2 2026 revenue growth of 38.2% and raised full-year revenue guidance.
Gross margin contracted from 76.4% to 63.8% as lower-margin products expanded, while the company recorded a twelve-month operating loss of $155 million and faces a securities class action lawsuit.
Shares of Hims & Hers Health trade at $29.02, with negative momentum signals and an 80% probability for a move to $28.05 to $29.98 in the next five days.

Revenue growth and guidance lifted amid shrinking margin and lawsuit pressure

Hims & Hers Health reported a 38.2% increase in revenue for fiscal Q2 2026 and raised its full-year revenue outlook, although gross margin fell significantly from 76.4% to 63.8% as lower-margin products grew faster. The company recorded an operating loss of $155 million for the twelve months ending June 2026 after posting a $126 million operating profit a year earlier. A securities class action lawsuit was filed against the company and certain officers, raising regulatory scrutiny over its practices. Hims & Hers Health also expanded its men's health offerings by launching new testosterone therapies and introduced Hers Hair to UK women.

Anton Kharitonov, expert at Traders Union, sees the recent revenue surge and raised outlook as overshadowed by deep margin compression and the sudden return to operational losses. He notes that unresolved litigation and increased regulatory risk further undermine investor confidence. Technically, the persistent negative momentum and failure to reclaim the 50-day moving average suggest limited upside. He stresses that oversold readings point to extended weakness rather than an imminent rebound. "Gross margin erosion and the pending lawsuit make downside risk dominant, so I remain very cautious on HIMS at these levels," Kharitonov says.

Viktoras Karapetjanc, expert at Traders Union, highlights the impressive 38.2% revenue growth and successful expansion of product offerings. He believes the raised full-year outlook and proactive market moves demonstrate strong operational momentum. According to Karapetjanc, bullish structure remains intact while long-term technical support holds. "Despite recent volatility, I see further growth potential as Hims & Hers Health continues to innovate and increase market share," he states.

Sholanke Dele, market strategist, sees sentiment turning negative as investors react to weakening margins and legal challenges. He notes that news of the securities class action lawsuit intensifies scrutiny and tempers market enthusiasm. Dele remains wary of near-term upside, pointing to the high probability forecast of a downward move. "With current headwinds and fragile sentiment, traders should be defensive until the outlook stabilizes," Dele advises.

Technical resistance emerges as negative momentum outweighs long-term support

Hims & Hers Health is currently trading just above its 20-day moving average at $29.01 and well above its 200-day moving average of $27.08, indicating ongoing long-term bullish support. The price remains slightly below the 50-day moving average at $29.11, with near-term resistance set at the Ichimoku Kijun of $29.06 and immediate support at $29.01. Momentum indicators are generally negative: the MACD is in sell territory, the ADX is neutral with muted trend strength, and the RSI, Stochastic RSI, and CCI all highlight oversold conditions. Bull/Bear Power is negative and oversold, while the Awesome Oscillator has a sell bias. Despite strong early gains and intraday volatility at 2.64%, the market is showing caution as the stock faces near-term resistance.

Earlier, analysts noted that Hims & Hers Health faced mixed technical signals and ongoing legal and regulatory risks that weighed on its overall outlook. The latest results reinforce these concerns by highlighting continued bearish momentum despite revenue growth, making near-term resistance at $29.06 a pivotal level for potential direction.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.